Cargando…

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo

Phenoxodiol (PXD) is a synthetic analogue of the plant isoflavone genistein with improved anticancer efficacy. Various properties and mechanisms of action have been attributed to the drug, the most important being its ability to sensitize resistant tumour cells to chemotherapy, which led to its fast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgaki, Sylvianna, Skopeliti, Margarita, Tsiatas, Marinos, Nicolaou, Katerina A, Ioannou, Kyriaki, Husband, Alan, Bamias, Aristotelis, Dimopoulos, Meletios A, Constantinou, Andreas I, Tsitsilonis, Ourania E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2009
Materias:	Molecular Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516540/ https://www.ncbi.nlm.nih.gov/pubmed/19220577 http://dx.doi.org/10.1111/j.1582-4934.2009.00695.x

Ejemplares similares

Glycosylation of Semi-Synthetic Isoflavene Phenoxodiol with a Recombinant Glycosyltransferase from Micromonospora echinospora ATCC 27932
por: Seo, Minsuk, et al.
Publicado: (2022)

Investigations of Electronic, Structural, and In Silico Anticancer Potential of Persuasive Phytoestrogenic Isoflavene-Based Mannich Bases
por: Mutahir, Sadaf, et al.
Publicado: (2023)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
por: Birmpilis, Anastasios I., et al.
Publicado: (2019)

The effects of phenoxodiol on the cell cycle of prostate cancer cell lines
por: Mahoney, Simon, et al.
Publicado: (2014)

Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?
por: Zagouri, Flora, et al.
Publicado: (2010)

Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology
por: Mystakidou, Kyriaki, et al.
Publicado: (2007)

Synthesis of Dextran–Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity
por: Yee, Eugene M. H., et al.
Publicado: (2019)

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
por: Gavalas, Nikos G., et al.
Publicado: (2010)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer
por: Howes, Jan B, et al.
Publicado: (2011)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model
por: Klein, Reuben, et al.
Publicado: (2007)

The role of high-dose chemotherapy in the treatment of testicular cancer
por: Karadimou, Alexandra, et al.
Publicado: (2010)

EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets
por: Stergiou, Ioanna E., et al.
Publicado: (2023)

Phenoxodiol sensitizes metastatic colorectal cancer cells to 5-fluorouracil- and oxaliplatin-induced apoptosis through intrinsic pathway
por: Yaylaci, Esra, et al.
Publicado: (2020)

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent
por: Papanagnou, Eleni-Dimitra, et al.
Publicado: (2018)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis
por: Karadimou, Alexandra, et al.
Publicado: (2010)

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells
por: Papadhimitriou, Stefanos I., et al.
Publicado: (2022)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates
por: Shulman, Lester M., et al.
Publicado: (2011)

Distinct type I interferon responses between younger women and older men contribute to the variability of COVID-19 outcomes: Hypothesis generating insights from COVID-19 convalescent individuals
por: Mavragani, Clio P., et al.
Publicado: (2022)

Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours
por: Mountzios, Giannis, et al.
Publicado: (2006)

Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes
por: Ioannou, Kyriaki, et al.
Publicado: (2013)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
por: Karadimou, Alexandra, et al.
Publicado: (2011)

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2015)

Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
por: Stefanou, Dimitra T., et al.
Publicado: (2021)

Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker
por: Birmpilis, Anastasios I., et al.
Publicado: (2022)

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
por: Bagratuni, Tina, et al.
Publicado: (2020)

Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
por: Gavalas, Nikos G., et al.
Publicado: (2013)

Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells
por: Skorda, Aikaterini, et al.
Publicado: (2019)

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
por: Orologas-Stavrou, Nikolaos, et al.
Publicado: (2020)

The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
por: Stofas, Anastasios, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vcgk8i13lt7bpq4l1b5gisqjgj